Related Experiment Video
Updated: Feb 12, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Stephen J Russell1, Glen N Barber2
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Selective destruction of neoplastic tissues by oncolytic viruses (OVs) leads to antigen-agnostic boosting of neoantigen-specific cytotoxic T lymphocyte (CTL) responses, making OVs ideal companions for checkpoint blockade therapy. Here we discuss the mechanisms whereby OVs modulate both adjuvanticity and antigenicity of tumor cells. Suppression of antitumor immunity after OV therapy has not been observed, possibly because viral antigen expression diminishes as the antiviral response matures, thereby progressively honing the CTL response to tumor neoantigens. By combining direct in situ tumor destruction with the ability to boost antitumor immunity, OVs also have the potential to be powerful standalone cancer therapies.
Insights
Oncolytic viruses (OVs) selectively destroy tumors, enhancing anti-tumor immune responses. This makes OVs effective companions for cancer therapies and potential standalone treatments.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Oncolytic viruses (OVs) selectively destroy neoplastic tissues.
- OVs can boost neoantigen-specific cytotoxic T lymphocyte (CTL) responses.
- OVs are considered ideal companions for checkpoint blockade therapy.
Purpose of the Study:
- To discuss the mechanisms by which OVs modulate tumor cell adjuvanticity and antigenicity.
- To explore the potential of OVs as standalone cancer therapies.
Main Methods:
- Discussion of OV mechanisms in cancer therapy.
- Analysis of immune response modulation by OVs.
Main Results:
- OV therapy does not appear to suppress antitumor immunity.
- Viral antigen expression diminishes as antiviral response matures, honing CTL response to tumor neoantigens.
- OVs combine direct tumor destruction with immune system boosting.
Conclusions:
- OVs enhance anti-tumor immunity by modulating tumor antigenicity and adjuvanticity.
- OVs show promise as potent standalone cancer therapies.
- OVs are valuable partners for checkpoint blockade therapy.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
What are Viruses?
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

